Edition:
India

Sucampo Pharmaceuticals Inc (SCMP.OQ)

SCMP.OQ on NASDAQ Stock Exchange Global Market

17.95USD
8:58pm IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$17.95
Open
$17.95
Day's High
$18.00
Day's Low
$17.95
Volume
197,119
Avg. Vol
315,457
52-wk High
$18.75
52-wk Low
$9.30

Select another date:

Tue, Jan 2 2018

BRIEF-Sucampo Pharmaceuticals Received Notification From FDA That It Has Extended PDUFA Goal Date By 3 Months

* SUCAMPO PHARMACEUTICALS - ON DEC 28, RECEIVED NOTIFICATION FROM U.S. FDA THAT IT HAS EXTENDED PDUFA GOAL DATE BY 3 MONTHS FOR SNDA FOR LUBIPROSTONE

Mallinckrodt to buy Sucampo for about $840 million

Mallinckrodt Plc said on Tuesday it would buy Sucampo Pharmaceuticals Inc for about $840 million to snap up constipation drug Amitiza and a clutch of experimental rare disease treatments, as it battles declining sales of its biggest drug, Acthar.

UPDATE 2-Mallinckrodt to buy Sucampo for about $840 mln

* Deal for $18/share, a premium of about 6 pct to Friday close

BRIEF-Sucampo Pharma Says If Merger Agreement Terminated, Co Agreed To Pay Mallinckrodt Fee Of $44 Million

* SUCAMPO PHARMACEUTICALS SAYS IF MERGER AGREEMENT TERMINATED UNDER CERTAIN CIRCUMSTANCES, CO AGREED TO PAY MALLINCKRODT FEE OF $44 MILLION - SEC FILING Source text : (http://bit.ly/2BUtNpK) Further company coverage:

BRIEF-Mallinckrodt To Buy Sucampo Pharmaceuticals For About $1.2 Bln

* MALLINCKRODT TO ACQUIRE SUCAMPO PHARMACEUTICALS FOR APPROXIMATELY $1.2 BILLION

Mallinckrodt to buy Sucampo Pharmaceuticals for about $1.2 bln

Dec 26 Mallinckrodt Plc said on Tuesday it would buy Sucampo Pharmaceuticals Inc in a deal valued at about $1.2 billion to gain access to its constipation drug, Amitiza.

BRIEF-ING Groep NV Reports 6.70 Pct Passive Stake In Sucampo Pharmaceuticals As Of Dec 7 - SEC Filing

* REPORTS A 6.70 PCT PASSIVE STAKE IN SUCAMPO PHARMACEUTICALS INC AS OF DEC 7 - SEC FILING Source text: (http://bit.ly/2yseEW4) Further company coverage:

BRIEF-Linden Capital Reports A 5.1 Pct Passive Stake In Sucampo Pharmaceuticals

* LINDEN CAPITAL L.P REPORTS 5.1 PERCENT PASSIVE STAKE IN SUCAMPO PHARMACEUTICALS INC AS OF DECEMBER 6, 2017 - SEC FILING Source text : [http://bit.ly/2jz2syj] Further company coverage:

Sucampo weighs sale after fielding takeover interest: Bloomberg

Sucampo Pharmaceuticals Inc is considering selling itself after receiving takeover interest, Bloomberg reported on Thursday, citing people familiar with the matter.

BRIEF-Sucampo reports Q3 GAAP earnings per share $0.19

* Q3 earnings per share view $0.25 -- Thomson Reuters I/B/E/S

Select another date: